US2008248006A1PendingUtilityA1

Process For Ex Vivo Formation of Mammalian Bone And Uses Thereof

Assignee: UNIV MICHIGANPriority: Dec 28, 1999Filed: May 13, 2008Published: Oct 9, 2008
Est. expiryDec 28, 2019(expired)· nominal 20-yr term from priority
A61P 19/00G01N 33/5026C12N 2503/00A61K 2035/126C12N 2501/105G01N 33/5044A61K 35/12C12N 2510/00C12N 5/0654G01N 33/502C12N 2503/02C12N 2501/165C12N 2500/90C12N 2501/15C12N 2501/155C12N 2500/14G01N 33/5008C12N 2501/585
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation.

Claims

exact text as granted — not AI-modified
1 . A method for producing bone ex vivo, comprising the steps of:
 a) obtaining an osteogenic cell or bone precursor cell;   b) culturing said cell under serum free conditions in the presence of one or more osteogenic growth factors; and   c) maintaining the cell cultures at cell densities that allow the formation of a bone cell spheroid,   whereby bone if formed by cells within said bone cell spheroid.   
     
     
         2 . The method of  claim 1 , wherein the osteogenic cell or bone precursor cell is of human origin. 
     
     
         3 . The method of  claim 1 , wherein the osteogenic cell or bone precursor cell is of bovine origin. 
     
     
         4 . The method of  claim 1 , wherein the osteogenic cell or bone precursor cell is of equine origin. 
     
     
         5 . The method of  claim 1 , wherein the osteogenic cell or bone precursor cell is of canine origin. 
     
     
         6 . The method of  claim 1 , wherein the osteogenic cell or bone precursor cell is of feline origin. 
     
     
         7 . The method of  claim 1 , wherein the osteogenic cell or bone precursor cell is of murine origin. 
     
     
         8 . The method of  claim 1 , wherein the osteogenic cell or bone precursor cell is of rat origin. 
     
     
         9 . The method of  claim 1 , wherein the osteogenic cell or bone precursor cell is of chick origin. 
     
     
         10 . The method of  claim 1 , wherein the growth factor is TGF-β1, TGF-β2, TGF-β1.2, VEGF, insulin-like growth factor I or II, BMP2, BMP4, or BMP7. 
     
     
         11 . The method of  claim 1 , wherein the growth factor is parathyroid hormone, calcitonin, interleukin-6, or interleukin-11. 
     
     
         12 . The method of  claim 1 , further comprising purifying the osteogenic cell or bone precursor cell by physico-chemical separation techniques. 
     
     
         13 . The method of  claim 12 , wherein the physico-chemical separation technique is equilibrium density separation. 
     
     
         14 . The method of  claim 1 , further comprising purifying the osteogenic cell or bone precursor cell by immuno-affinity isolation. 
     
     
         15 . The method of  claim 14 , wherein the immuno-affinity isolation utilizes immune adhesion, immuno-column chromatography, or fluorescence-activated cell sorting. 
     
     
         16 . The method of  claim 14 , wherein the immuno-affinity isolation utilizes antibodies to osteocalcin, osteonectin, or alkaline phosphatase, or combinations thereof. 
     
     
         17 . The method of  claim 1 , wherein said cell-densities at the initiation of the culture are from about 1.0×10 3  to about 1×10 6  cells per cm 2 . 
     
     
         18 . The method of  claim 1 , further comprising implanting the cells in vivo. 
     
     
         19 . A method of providing bone tissue to a mammal, comprising obtaining a bone cell spheroid and implanting the bone cell spheroid into said mammal. 
     
     
         20 . The method of  claim 19 , wherein the bone cell spheroid is implanted in one or more of alginate gels, collagen gels, or fibrin gels. 
     
     
         21 . The method of  claim 19 , wherein the bone cell spheroid is implanted in one or more of polylactic acid, polyglycolic acid or PGLA. 
     
     
         22 . The method of  claim 19 , wherein the bone cell spheroid is implanted in or in conjunction with hydroxyapatitic, other apatitic compounds, devitalized animal bone, devitalized human bone, or porous ceramic structures. 
     
     
         23 . The method of  claim 19 , wherein the implantation is made in conjunction with orthopedic surgery and/or orthopedic devices, such as hip implants, knee implants, or spinal fusions. 
     
     
         24 . The method of  claim 19 , wherein the implantation is made in conjunction with oral surgery and/or dental implants. 
     
     
         25 . The method of  claim 19 , wherein the implantation is made in conjunction with plastic surgery. 
     
     
         26 . The method of  claim 19 , wherein the implantation is in conjunction with periodontal repairs. 
     
     
         27 . The method of  claim 19 , wherein the implantation is into bone-forming tissue. 
     
     
         28 . The method of  claim 19 , wherein the implantation is into a wound. 
     
     
         29 . The method of  claim 19 , wherein the mammal has a bone disease such as osteoporosis, Vitamin D deficiency, Osteotitis deformans, Von Recklinghausen's Disease. 
     
     
         30 . A method for producing bone ex vivo, comprising the steps of:
 a) obtaining an osteogenic cell or bone precursor cell;   b) culturing said cell under serum free conditions in the presence of one or more osteogenic growth factors;   c) maintaining the cell cultures at cell-densities that allow the formation of a bone cell spheroid, whereby bone is formed by cells within said bone cell spheroid; and,   d) removing the cellular elements from the formed bone cell spheroid and using resulting bone in vivo.   
     
     
         31 . A method for producing bone ex vivo, comprising the steps of:
 a) obtaining an osteogenic cell or bone precursor cell;   b) culturing said cell under serum free conditions in the presence of one or more osteogenic growth factors;   c) contacting said cell with a recombinant vector that directs the expression of a protein that modifies bone cell spheroid formation; and   d) initiating the cell cultures at cell-densities that allow the formation of a bone cell spheroid   whereby bone is formed by cells within said bone cell spheroid.   
     
     
         32 . The method of  claim 31 , wherein said protein that enhances bone cell spheroid formation is TGF-β1, TGF-β2, TGF-β1.2, PTH, calcitonin, interleukin-6 or interleukin-11, BMP2, BMP4, BMP7, collagen, osteonectin, osteopontin, bone sialoprotein, osteocalcin, insulin-like growth factors I or II, VEGF, integrin α chains, integrin β chains, selecting, fibronectin, thrombospondin or cadherin. 
     
     
         33 . A method for using bone for bone repair in a subject, comprising the steps of:
 a) obtaining an osteogenic cell or bone precursor cell;   b) culturing said cell under serum free conditions in the presence of one or more osteogenic growth factors; and,   c) contacting said cell with a recombinant vector that expresses a protein that enhances bone cell spheroid formation;   d) maintaining the cell cultures at cell-densities that allow the formation of a bone cell spheroid, whereby bone is formed by cells within said bone cell spheroid;   e) removing the cellular elements from the ex vivo formed bone; and   f) using said bone to effect repair.   
     
     
         34 . A method for identifying a gene involved in bone formation, bone repair and/or bone disease, comprising the steps of:
 a) obtaining an osteogenic cell or bone precursor cell;   b) culturing said cell under serum free conditions in the presence of one or more growth factors of the TGF-β gene superfamily;   c) maintaining the cell cultures at cell-densities that allow the formation of a bone cell spheroid; and   d) identifying a gene that is over or under expressed during the formation of a bone cell spheroid and not so expressed in the untreated osteogenic or bone precursor cell.   
     
     
         35 . A method for identifying a modulator of bone formation, bone repair and/or bone disease, comprising the steps of:
 a) obtaining an osteogenic cell or bone precursor cell;   b) culturing said cell under serum free conditions in the presence of a candidate modulator in the absence of one or more osteogenic growth factors;   c) measuring bone cell spheroid formation; and   d) comparing the formation of bone cell spheroid with that observed in the absence of the modulator.   
     
     
         36 . The method of  claim 35 , further comprising a step of culturing an osteogenic cell or bone precursor cell in the presence of one or more osteogenic growth factors. 
     
     
         37 . A method for producing a modulator of bone formation, bone repair and/or bone disease comprising the steps of:
 a) obtaining an osteogenic cell or bone precursor cell;   b) culturing said cell under serum free conditions in the presence of a candidate modulator in the presence of one or more osteogenic growth factors;   c) measuring bone cell spheroid formation;   d) comparing the formation of bone cell spheroid with that observed in the absence of the modulator; and   e) producing a modulator so identified.   
     
     
         38 . A bone cell spheroid made by the process of:
 a) obtaining an osteogenic cell or bone precursor cell;   b) culturing said cell under serum free conditions in the presence of one or more osteogenic growth factors; and   c) maintaining the cell cultures at cell densities that allow the formation of a bone cell spheroid, whereby bone is formed by cells within said bone cell spheroid.

Join the waitlist — get patent alerts

Track US2008248006A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.